Our Mission
To develop and commercialize genetic treatments for suffering patients of small populations.
|| OUR STORY
{ 2 }
PIONEERING RARE DISEASE THERAPY
From a Father’s Fight to a Global Solution: The Evolution of AlphaRose Therapeutics
Casey has been fighting for his daughter, and other children affected by genetic diseases, since 2016. He has become a leading voice in the rare disease field through his non-profit foundation To Cure A Rose Foundation, and Contract Research Organization, RareLabs. In under a year, Casey and his science team successfully developed a preclinical treatment for his daughter’s disease.
Throughout this journey, Casey identified a critical need for an innovative business model in the biotech and pharmaceutical sectors to ensure that their process could reach millions of children like Rose—an area that many other companies have overlooked. In 2024, he founded AlphaRose Therapeutics to address this gap.
|| PRECISION MEDICINE
{ 3 }
A NEW STANDARD IN PRECISION MEDICINE
Legendary Experience Meets Radical Innovation: The Vision Behind AlphaRose Therapeutics
Public-benefit corporation, AlphaRose Therapeutics, brings together Casey McPherson with industry leaders Belinda Termeer, Masako Nakamura, and Alan Walts, who worked alongside Henri Termeer at Genzyme in pioneering the field of rare disease biotech.
Together, they are building a precision medicine company to change how the industry develops and commercializes genetic disease treatments.
Our Vision
To eradicate genetic disease by 2040 and usher in a new age of accessible personalized medicines for patients.
Our Legacy
To leverage decades of pioneering biotech expertise to bridge the gap between scientific discovery and global patient delivery.
|| THE PEOPLE
{ 4 }
THE PEOPLE BEHIND THIS
Built by operators, not observers.
Co-Founder & CEO
Casey McPherson
Rose’s father. Built To Cure A Rose Foundation, assembled the team that created Rosiphersen in under a year, and drives the company’s vision, culture, and fundraising.
COO & President
Masako Nakamura
Oversees clinical development, commercialization, and pipeline operations. Leads execution of Rosiphersen’s path to market and manages grant funding strategy.
Chief Scientific Officer
Robert Cabrera, Ph.D.
Baylor College of Medicine. Leads all preclinical work across indications and oversees new technology platform development, including biomarker and toxicity programs.
Head of R&D
Jeffrey Brown, Ph.D., MBA
20+ years in preclinical drug development across Pfizer, BMS, Alexion, Voyager, and Wave Life Sciences. Has advanced multiple programs from concept to clinical candidate across RNA, AAV, and small molecule modalities.
Co-Founder & Executive Chairman
Alan Walts, Ph.D.
Former head of Genzyme Ventures (now Sanofi Ventures). MIT Ph.D. in Chemistry. Harvard Business School. Co-founded multiple life sciences companies. Advisor to the Termeer family office.
|| CONTACT US
{ 5 }
GET IN TOUCH
We're Here to Help
Whether you have a project in mind, need guidance, or want to explore collaboration opportunities — reach out anytime. Our team will respond quickly and provide everything you need to move forward.